4-fluoro-5-[2-(3R-hydroxy-pyrrolidine-1-carbonyl)-thieno[3,2-b]pyridin-7-yloxy]-2-methyl-indole-1-carboxylic acid methylamide | 596794-28-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-fluoro-5-[2-(3R-hydroxy-pyrrolidine-1-carbonyl)-thieno[3,2-b]pyridin-7-yloxy]-2-methyl-indole-1-carboxylic acid methylamide
• 英文别名: 4-fluoro-5-[2-[(3R)-3-hydroxypyrrolidine-1-carbonyl]thieno[3,2-b]pyridin-7-yl]oxy-N,2-dimethylindole-1-carboxamide
• CAS: 596794-28-4
• 化学式: C₂₃H₂₁FN₄O₄S
• 分子量: 468.509
• InChiKey: JWBKIDSJUHCNGM-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use
  申请人：——

  公开号：US20040019065A1

  公开（公告）日：2004-01-29

  The invention relates to compounds represented by the formula I 1 and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R 1 and R 11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  这项发明涉及由公式I表示的化合物，以及这些化合物的前药、药学上可接受的盐或溶剂，其中X、R1和R11如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给予公式I化合物来治疗哺乳动物的过度增殖性疾病的方法。
• INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
  申请人：PFIZER INC.

  公开号：EP1483268A2

  公开（公告）日：2004-12-08
• US6833456B2
  申请人：——

  公开号：US6833456B2

  公开（公告）日：2004-12-21
• [EN] INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS, AND METHODS FOR THEIR USE<br/>[FR] DERIVES INDOLYL-UREE DE THIENOPYRIDINES UTILISES COMME AGENTS ANTIANGIOGENIQUES, ET LEURS METHODES D'UTILISATION
  申请人：PFIZER

  公开号：WO2003074529A2

  公开（公告）日：2003-09-12

  The invention relates to compounds represented by the formula FI and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.